10 Things Worth Pay...
Health Care: Drugs
Ariad Pharmaceuticals (ARIA: NASDAQ)
$15.63 -0.08 | -0.51%
06/04/12 - 04:00 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -123.60M | 85.25M | -80.01M | -71.05M |
| Operating Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 373.00K | 3.18M | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 816.00K | 2.10M | -1.68M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | -992.00K |
| (Decrease) Increase In Payables | 2.39M | -1.68M | -4.56M | 4.32M |
| (Decrease) Increase In Other Current Liabilities | 5.11M | -850.00K | -2.91M | 2.60M |
| (Increase) Decrease In Other Working Capital | 1.74M | -112.28M | 15.98M | 10.76M |
| Other Non-Cash Items | 56.11M | 25.84M | 13.27M | 4.77M |
| Net Cash From Continuing Operations | -53.26M | 6.42M | -51.90M | -48.25M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -53.26M | 6.42M | -51.90M | -48.25M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 22.43M | 60.17M |
| Purchases of Property, Plant & Equipment | -2.12M | -2.04M | -3.51M | -7.74M |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | -7.60M | -57.26M |
| Other Cash from Investing Activities | 0.00 | 0.00 | -50.00K | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -2.12M | -2.04M | 11.27M | -4.84M |
| Issuance of Debt | 4.38M | 0.00 | 0.00 | 10.50M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 255.93M | 60.93M | 58.94M | 385.00K |
| Repayment of Long-Term Debt | -1.47M | -2.04M | -1.49M | -1.42M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -827.00K | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 258.01M | 58.88M | 57.45M | 9.47M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 202.63M | 63.27M | 16.82M | -43.62M |
Portfolios with ARIA
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor7 Cancer Drug Stocks to Kno...
- ContributorStocks At New 52-Week Highs...
- ContributorStocks Rising On Unusual Vo...
- Contributor10 Biotech Stocks Loved and...
- ContributorEarnings Short Squeeze Play...
- Contributor5 Stocks Under-$10 Setting ...
- Userlance and donna
- ContributorHot Biotech Trades for Seco...
Latest ARIA Headlines from TheStreet
- ASCO 2012 Live Blog -- Monday 06.04.12 | 06:06 am
- ASCO '12: Ariad Pharma Leukemia Drug Posts Improved Response Rates 06.04.12 | 12:06 am
- Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer 05.25.12 | 05:05 am
- The Next Big Thing in Biotech: ASCO Conference
05.25.12 | 05:05 am - ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- Ariad Stock Hits New 52-Week High (ARIA) 05.11.12 | 01:05 pm
- Ariad Reaches New 52-Week High (ARIA) 04.27.12 | 11:04 am
- Endocyte Shares Rise on Merck Cancer Deal 04.16.12 | 09:04 am
- Analysts' Actions: ARIA, EA, HGSI, BBBY 04.12.12 | 08:04 am
Press Releases for ARIA
- ARIAD Announces Updated Data From Pivotal PACE Trial Of Ponatinib, Its Investigational Pan-BCR-ABL Inhibitor - Business Wire 06.04.12 | 07:06 am
- ARIAD To Present At Upcoming Investor Conferences - Business Wire 05.30.12 | 07:05 am
- ARIAD To Present At Bank Of America Merrill Lynch 2012 Health Care Conference - Business Wire 05.10.12 | 07:05 am
- ARIAD To Present At The Deutsche Bank 37th Annual Health Care Conference - Business Wire 04.30.12 | 07:04 am
- ARIAD To Webcast Conference Call On First Quarter 2012 Financial Results - Business Wire 04.25.12 | 07:04 am
- ARIAD Presents New Preclinical Data On Ponatinib And AP26113 - Business Wire 04.02.12 | 09:04 am
- ARIAD Announces Presentations Of Preclinical Data At American Association For Cancer Research Annual Meeting - Business Wire 03.26.12 | 07:03 am
- Merck And ARIAD Pharmaceuticals Provide Update On FDA Advisory Committee Vote On Investigational Medicine Ridaforolimus For The Treatment Of Metastatic Soft-Tissue Or Bone Sarcomas - Business Wire 03.20.12 | 07:03 pm
- ARIAD To Present At Barclays Capital Global Healthcare Conference - Business Wire 03.06.12 | 07:03 am
- ARIAD Reports 2011 Financial Results And Outlines Key Development And Commercialization Plans For 2012 - Business Wire 02.28.12 | 07:02 am
Partner Headlines for ARIA
- AACR Annual Oncology Meeting: A Look Into Various Abstracts - Seeking Alpha 03.27.12 | 09:03 am
- Zacks #5 Rank Additions for Thursday - Tale of the Tape - Zacks 03.22.12 | 09:03 am
- Zacks #5 Rank Additions for Wednesday - Tale of the Tape - Zacks 03.14.12 | 09:03 am
- Zacks #5 Rank Additions for Tuesday - Tale of the Tape - Zacks 02.28.12 | 09:02 am
- Notable Put Options Activity in ARIAD Pharmaceuticals - Benzinga 02.02.12 | 01:02 pm
- Biotech Equities Continue To Benefit From Discoveries And Acquisitions In 2012 - Seeking Alpha 01.27.12 | 09:01 am
- 10 Stocks That Made New Highs On Friday: Hedging Costs - Seeking Alpha 01.15.12 | 07:01 am
- Using Friday's Option Trades To Find Investment Ideas - Seeking Alpha 01.13.12 | 06:01 pm
- YM's Positive Results Have Incyte Investors Worried - Seeking Alpha 12.15.11 | 09:12 am
- Rodman & Renshaw Maintain Market Outperform Rating and $15 PT on ARIAD Pharmaceuticals - Benzinga 11.01.11 | 09:11 am
